Tirzepatide
Approved weight-loss, diabetes, sleep-apnea drug
The drug in Mounjaro and Zepbound
Match every finding to its exact substance, formulation, route and study population. A related molecule or approved medicine does not validate a catalog vial.
Simplified drawing of a chain of 39 amino acids, with its fatty-acid tail
At a glance
Why people take it. And what backs it up.
-
Lose weight
Approved for obesity (Zepbound)
Approved as Zepbound for adults with obesity, or overweight plus a related illness; on the top dose adults lost about 21%, more than semaglutide.
Sources (3)
-
LabelZepbound prescribing information (FDA, revised 08/2026) (opens in a new tab)
“to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition”
-
“-20.9% (95% CI, -21.8 to -19.9) with 15-mg doses and -3.1% (95% CI, -4.3 to -1.9) with placebo”
-
“Among participants with obesity but without diabetes, treatment with tirzepatide was superior to treatment with semaglutide with respect to reduction in body weight and waist circumference at week 72.”
-
-
Control type 2 diabetes
Approved for type 2 diabetes (Mounjaro)
Prescribed as Mounjaro to lower blood sugar in adults and children 10 and older with type 2 diabetes, alongside diet and exercise.
Sources (2)
-
LabelMounjaro prescribing information (FDA, revised 08/2026) (opens in a new tab)
“as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus”
-
LabelMounjaro prescribing information (FDA, revised 08/2026): clinical studies (opens in a new tab)
“Monotherapy with MOUNJARO 5 mg, 10 mg and 15 mg once weekly for 40 weeks resulted in a statistically significant reduction in HbA1c compared with placebo”
-
-
Ease sleep apnea
Approved for sleep apnea with obesity
Approved as Zepbound for adults with obesity and moderate to severe sleep apnea; in trials, breathing pauses during sleep fell by up to 59%.
Sources (2)
-
LabelZepbound prescribing information (FDA, revised 08/2026) (opens in a new tab)
“to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity”
-
“the AHI decreased significantly by up to 29.3 events per hour (a 58.7% change from baseline) among the participants who received tirzepatide”
-
-
Microdose for inflammation and cravings
People report it, not studied
Many take tiny doses, well below the 2.5 mg starting dose, to calm inflammation or quiet food cravings rather than to lose much weight.
Sources (3)
-
“I do still experience hunger, but the food noise or constant need to snack is gone. I also have not experienced any binge urges.”
-
“I started using Tirz in early July at a microdose level (slowly worked up to 1 mg/ week) to help with inflammation caused from prior mold exposure”
-
ClinicAgelessRx (telehealth clinic): Microdosing Tirzepatide (opens in a new tab)
“A low-dose GLP-1 approach designed to work in sync with the body, which may help minimize side effects, quiet cravings, and support moderate weight loss.”
-
-
Keep weight off
Early human studies
After reaching goal, many stretch doses weeks apart or drop to a low dose to hold their weight for less money.
Sources (4)
-
ForumReddit r/MounjaroMaintenance: “Level after 31 days on 2.5mg” (September 2026) (opens in a new tab)
“now on maintenance still taking 2.5mg but now every 31 days”
-
“Because of the cost of the medication, I have experimented with spacing out my doses and buying the higher dose pens but giving myself smaller doses”
-
StudyWong et al., Obesity, 2026 (case series of 30 adults; PubMed abstract) (opens in a new tab)
“In patients with prior weight loss and metabolic improvement on GLP1 therapy, reduced-frequency maintenance dosing preserved outcomes.”
-
“Both real-world and virtual patients maintained significant weight loss under reduced dosing frequencies.”
-
Evidence briefing
Sources checkedWhat the sources support.
Tirzepatide is FDA-approved as Mounjaro for type 2 diabetes and Zepbound for chronic weight management and obesity-related sleep apnea; 2026 Mounjaro labeling adds cardiovascular risk reduction for a defined high-risk type 2 diabetes population. Research-vial products are not the approved products.
Approval does not establish the identity, purity or equivalence of research-vial products.
The research. What’s been studied.
TapClick a dotted word to see what it means.
-
Human evidence
Greater weight loss
About 21% average weight loss at the top dose over 72 weeks, and more than semaglutide in a head-to-head trial.
-
Human evidence
Blood sugar control
Produced some of the largest A1c reductions seen in type 2 diabetes trials.
-
Human evidence
Sleep apnea improvement
FDA-approved for obstructive sleep apnea with obesity; it cut breathing interruptions during sleep substantially.
-
Human evidence
Appetite control
Reduces hunger and portion sizes through two gut-hormone pathways ( and GIP).
-
Early human studies
Better metabolic markers
Trials also showed lower blood pressure, triglycerides and liver fat.
What do these labels mean?
- Human evidence: approved-drug data or larger human studies, within the populations and uses studied.
- Early human studies: small, preliminary or limited human studies.
- Animal & lab studies: animal or laboratory findings that do not establish effects in people.
- Unverified: a proposed use or claim without verified supporting clinical evidence.
How each claim was reviewed (5)
Reported effects and evidence.
A citation may support, qualify or correct a claim. Read the study scope; a laboratory result is not an established benefit in people. Each review covers a claim as it was first collected; the tiles above show the collection’s current wording.
-
Human RCT; two separate trials
Review of “Greater weight loss”
SURMOUNT-1 reported 20.9% mean loss at its highest studied dose over 72 weeks. SURMOUNT-5 separately favored tirzepatide over semaglutide.
Limitations and applicability. Separate SURMOUNT-1 from head-to-head SURMOUNT-5; do not imply indirect cross-trial comparison.
Original collected claim and review history
Original title: Greater weight loss
About 21% average weight loss at the top dose over 72 weeks, and more than semaglutide in a head-to-head trial.
Original headline statistic: About 21%
Original label: proven. Preserved for traceability; the reviewed wording above qualifies this record.
Record tirzepatide:benefit:1 · Annotated 2026-10-01 · Review method
-
Human RCT / approved diabetes indication
Review of “Blood sugar control”
In SURPASS-2, tirzepatide reduced HbA1c more than the semaglutide comparator in adults with type 2 diabetes.
Limitations and applicability. “Some of the largest” is an undefined ranking. Provide trial-specific effect rather than superlative.
Original collected claim and review history
Original title: Blood sugar control
Produced some of the largest A1c reductions seen in type 2 diabetes trials.
Original label: proven. Preserved for traceability; the reviewed wording above qualifies this record.
Record tirzepatide:benefit:2 · Annotated 2026-10-01 · Review method
-
Approved indication; human phase 3 RCT
Review of “Sleep apnea improvement”
Zepbound is approved for moderate-to-severe obstructive sleep apnea in adults with obesity; trials reduced apnea–hypopnea events.
Limitations and applicability. Approval is for moderate-to-severe OSA in adults with obesity, using the approved product.
- https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
- https://pubmed.ncbi.nlm.nih.gov/38912654/
Original collected claim and review history
Original title: Sleep apnea improvement
FDA-approved for obstructive sleep apnea with obesity; it cut breathing interruptions during sleep substantially.
Original label: proven. Preserved for traceability; the reviewed wording above qualifies this record.
Record tirzepatide:benefit:3 · Annotated 2026-10-01 · Review method
-
Approved-product pharmacology
Review of “Appetite control”
Tirzepatide activates GIP and GLP-1 receptors and reduces caloric intake through effects on appetite.
Limitations and applicability. Mechanistic description is reasonable; distinguish receptor activity from separately proven contribution of each pathway.
Original collected claim and review history
Original title: Appetite control
Reduces hunger and portion sizes through two gut-hormone pathways (GLP-1 and GIP).
Original label: proven. Preserved for traceability; the reviewed wording above qualifies this record.
Record tirzepatide:benefit:4 · Annotated 2026-10-01 · Review method
-
Human trial secondary outcomes; bundled claim
Review of “Better metabolic markers”
Trials reported improvements in selected cardiometabolic measures. Present blood pressure, triglyceride and liver-fat findings as separate endpoints.
Limitations and applicability. Blood pressure/lipids have trial evidence. This citation does not verify the liver-fat component; split and source separately.
Original collected claim and review history
Original title: Better metabolic markers
Trials also showed lower blood pressure, triglycerides and liver fat.
Original label: early. Preserved for traceability; the reviewed wording above qualifies this record.
Record tirzepatide:benefit:5 · Annotated 2026-10-01 · Review method
The research in detail
Evidence category
FDA-approved (US)
In SURMOUNT-1, adults with obesity lost about 21% of body weight on the highest dose over 72 weeks. In a head-to-head trial (SURMOUNT-5) it produced more weight loss than semaglutide.
Evidence is assessed claim by claim above. Regulatory approval, study design, findings and relevance are separate questions; there is no single evidence score.
Risks and unknowns. What to know first.
Collected cautions follow. These are not an exhaustive or independently validated safety assessment; claim references do not automatically support every caution.
- Similar to semaglutide: GI upset, possible gallbladder disease and pancreatitis, and the rodent thyroid-tumor warning.
- Can reduce the reliability of birth-control pills around dose changes.
What people report
-
Regulator
As of 31 May 2026 the FDA had received more than 730 adverse-event reports for compounded tirzepatide, including reports linked to doses beyond the label (larger single doses, more frequent doses or faster increases). It also warns about products sold “for research purposes”.
-
Regulator
The FDA notes one adverse event (redness, swelling, pain and a red lump at the injection site) from a product labelled as compounded tirzepatide that the named pharmacy had not actually made.
Source: FDA: FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (opens in a new tab)
-
User reports
Grey-market guides warn that vendors sometimes mislabel or ship low-quality product, and tell buyers to lab-test for purity (98% or more) and a fill within about 15% of the label.
Source: Stairway to Gray: “Getting Started with Gray Market Tirzepatide” (opens in a new tab)
Show all 6 cautionsShow fewer cautions
-
User reports
A pharmacist quoted by Yahoo Life said many home mixers use a mixed vial for about four months, although pharmacy guidance limits reconstituted tirzepatide to 28 days, raising contamination and potency risks.
-
User reports
Microdosers report delayed nausea several days after doses as low as 1.25 mg.
Source: Reddit r/GLP1microdosing: “Delayed nausea” (September 2026) (opens in a new tab)
-
User reports
A user extracting the leftover “golden dose” from the end of a pen with an insulin syringe accidentally drew 60 units instead of 6, about 10 times their usual microdose.
Published dosing records. What the approved label says.
Historical label and trial records for the named product, route, population and indication. These records are not a personal schedule or a validated regimen for a catalog vial. Source attribution does not establish applicability.
Zepbound
Long-term weight management in adults with obesity, or with overweight and a weight-related health problem. Also moderate to severe obstructive sleep apnea in adults with obesity.
Source: Zepbound prescribing information (FDA, revised 08/2026) (opens in a new tab)
- How
- Injection under the skin (belly or thigh; back of the upper arm if someone else gives it)
- How often
- Once a week
- How long
- Ongoing
Dose, step by step
- Weeks 1–4 2.5 mg
- Weeks 5–8Can stay on 5 mg
- Weeks 9–12 7.5 mg (only if needed)
- Weeks 13–16Can stay on 10 mg (only if needed)
- Weeks 17–20 12.5 mg (only if needed)
- Week 21 onCan stay on 15 mg (only if needed)
Limit. 15 mg once a week.
- Each step lasts at least 4 weeks; the weeks shown are the fastest the label allows. For weight loss, going past 5 mg is optional: the stay-on doses are 5, 10 or 15 mg. For sleep apnea, the stay-on doses are 10 or 15 mg, so the dose must rise to at least 10 mg.
- If a maintenance dose is not tolerated, the label says to consider a lower one.
- Missed dose: given within 4 days (96 hours); after that it is skipped. The weekly day can be changed if doses stay at least 3 days (72 hours) apart.
Mounjaro
Type 2 diabetes (blood sugar control) in adults and in children 10 and older. Also lowers heart risk in adults with type 2 diabetes who are at high risk.
Source: Mounjaro prescribing information (FDA, revised 08/2026) (opens in a new tab)
- How
- Injection under the skin (belly or thigh; back of the upper arm if someone else gives it)
- How often
- Once a week
- How long
- Ongoing
Dose, step by step
- Weeks 1–4 2.5 mg
- Weeks 5–8 5 mg (only if needed)
- Weeks 9–12 7.5 mg (only if needed)
- Weeks 13–16 10 mg (only if needed)
- Weeks 17–20 12.5 mg (only if needed)
- Week 21 on 15 mg (only if needed)
Limit. 15 mg once a week for adults; 10 mg once a week for children.
- Each increase is only for when more blood sugar control is needed, after at least 4 weeks on the current dose; people stay on the dose that works. The weeks shown are the fastest the label allows. Children stop at 10 mg.
- Missed dose: given within 4 days (96 hours); after that it is skipped.
These are the label’s doses for the approved medicine, started and adjusted by a prescriber. A research vial is not that medicine: no regulator has checked what’s in it, or how much.
Community protocols. Reported online. Not clinically validated.
Community reports Collection date: 30 Sep 2026Grey-market users mostly copy the label ladder (2.5 mg, rising 2.5 mg at a time) using research vials measured in syringe units, but often climb more slowly. Microdosing below 2.5 mg (about 0.15–2 mg a week) has become a mainstream telehealth and forum trend, and splitting the weekly dose or stretching the gap between doses is also common.
Grey-market vials following the label ladder
Collected report · exact form and route are only as reported below. Source date and reporter identity are not separately verified. Collection checked 30 Sep 2026; presentation annotated 2026-10-01.
- Forum: Stairway to Gray (grey-market community guide): “Getting Started with Gray Market Tirzepatide”
- Forum: Stairway to Gray (same guide)
- Forum: Stairway to Gray (same guide)
- Forum: Reddit r/tirzepatidecompound wiki: “Tirzepatide Dosing Guide”
Frequency labels describe this collection, not a measured population. Contradictory records remain available.
Details and sourcesHide details
- Dose
- 2.5 mg, then up in 2.5 mg steps (to 15 mg at most)
- How often
- Once a week (every 7 days)
- Route
- Injection under the skin (belly, thigh or upper arm)
- Timing
- Same day each week
- How long
- Open-ended
- Ramp
- Every 4 weeks on paper, but many move up far more slowly, sometimes every 2 months or more
- Mixing
- For example 60 mg vial + 3 mL bacteriostatic water (20 mg/mL, so 10 mg = 50 units); “1 mL for every 10 mg” is a common rule. Vials come in 10-vial “kits” (for example 10 × 30 mg).
- Buyers are urged to have each batch lab-tested for identity, purity and fill.
- Many users with compounded pharmacy vials follow the same ladder converted to syringe units.
Sources (4)
-
“Increase every 4 weeks based on tolerance, but many take this much slower. Sometimes moving up in dose every 2 months or more after adjusting to the 2.5mg starter dose.”
-
ForumStairway to Gray (same guide) (opens in a new tab)
“A 60mg vial reconstituted with 3mL BAC water = 20mg/mL concentration”
-
ForumStairway to Gray (same guide) (opens in a new tab)
“Example: 1mL BAC for every 10mg powder = easy dosing.”
-
ForumReddit r/tirzepatidecompound wiki: “Tirzepatide Dosing Guide” (opens in a new tab)
“Weeks 1–4: 2.5mg once weekly”
Microdosing (below 2.5 mg)
Collected report · exact form and route are only as reported below. Source date and reporter identity are not separately verified. Collection checked 30 Sep 2026; presentation annotated 2026-10-01.
- Review: medRxiv preprint: “Weight Loss With Microdose Tirzepatide” (September 2026, telehealth records)
- Forum: Reddit r/GLP1microdosing: “My Tirz Microdose experience with BED” (September 2026)
- Forum: Reddit r/GLP1microdosing: “Started at 0.15mg tirzepatide” (September 2026)
- Practitioner: Dr. Tyna Moore (naturopathic physician), Substack
Frequency labels describe this collection, not a measured population. Contradictory records remain available.
Details and sourcesHide details
- Dose
- About 0.15–2 mg (telehealth programs commonly 1–2 mg; some start at 0.15 mg)
- How often
- Once a week
- Route
- Injection under the skin
- How long
- Open-ended
- Ramp
- Often small weekly steps (one provider: 0.15 mg, then up 0.05 mg a week)
- Mixing
- Drawn as a few units from a 2.5 mg/0.5 mL vial, or set by counting clicks on a 2.5 mg KwikPen (10 clicks ≈ 0.43 mg in one user’s account)
- Used for binge-eating control, swelling (lipedema), inflammation, or to avoid side effects, not only for weight loss.
- The originator of GLP-1 “microdosing” says 2.5 mg is a standard dose, not a microdose.
Sources (4)
-
“who initiated compounded injectable tirzepatide at a microdose of 1 or 2 mg/week (below the standard 2.5 mg/week starting dose).”
-
“Current dose: 0.43mg weekly (10 clicks on 2.5mg KwikPen).”
-
ForumReddit r/GLP1microdosing: “Started at 0.15mg tirzepatide” (September 2026) (opens in a new tab)
“My provider started me at 3 units of a 2.5mg/0.5ml Zepbound vial. That’s 0.15mg. Then up 1 unit, so 0.05mg, a week.”
-
PractitionerDr. Tyna Moore (naturopathic physician), Substack (opens in a new tab)
“If you started on 0.25 mg of semaglutide or 2.5 mg of tirzepatide, you were started on a conventional standard dose.”
Show all 4 protocolsShow fewer protocols
Split dosing
Collected report · exact form and route are only as reported below. Source date and reporter identity are not separately verified. Collection checked 30 Sep 2026; presentation annotated 2026-10-01.
- Forum: Reddit r/survodutide: “Adding Surv to my Tirz” (November 2025)
- Forum: Reddit r/survodutide: “Adding Survo to Tirz” (September 2025)
- Forum: Reddit r/Peptides: reply in “Reta Dosing” (August 2026)
Frequency labels describe this collection, not a measured population. Contradictory records remain available.
Details and sourcesHide details
- Dose
- Same weekly total, divided (for example 5 mg as 2 × 2.5 mg)
- How often
- Twice a week, or every 3–6 days
- Route
- Injection under the skin
- Timing
- For example Monday and Thursday
- Done to smooth out side effects and hunger late in the week. Common among grey-market users because vials make any dose possible.
Sources (3)
-
ForumReddit r/survodutide: “Adding Surv to my Tirz” (November 2025) (opens in a new tab)
“I’m on 5mg total weekly on Tirz. I split dose on Monday and Thursday.”
-
ForumReddit r/survodutide: “Adding Survo to Tirz” (September 2025) (opens in a new tab)
“I take my tirz every 6 days”
-
ForumReddit r/Peptides: reply in “Reta Dosing” (August 2026) (opens in a new tab)
“You can also split doses. No need for weekly. I do Tirz 1.5mg every 3 days.”
Stretching the interval for maintenance
Collected report · exact form and route are only as reported below. Source date and reporter identity are not separately verified. Collection checked 30 Sep 2026; presentation annotated 2026-10-01.
- Forum: Reddit r/Tesamorelin: “Looking for advice on peptide sequencing” (July 2026)
- Forum: Reddit r/MounjaroMaintenance: “Level after 31 days on 2.5mg” (September 2026)
- Forum: Reddit r/MounjaroMaintenance: “Stretching out pen life without provider pushback” (September 2026)
- Forum: Reddit r/Eloralintide: “1+ year after study update” (June 2026)
Frequency labels describe this collection, not a measured population. Contradictory records remain available.
Details and sourcesHide details
- Dose
- Usually 2.5 mg, or a partial pen dose
- How often
- Every 2 weeks up to about once a month, or only when hunger returns
- Route
- Injection under the skin
- How long
- Long-term maintenance
- Used after reaching goal weight to cut cost and side effects. Some also take smaller doses from higher-strength pens to make a pen last longer.
Sources (4)
-
ForumReddit r/Tesamorelin: “Looking for advice on peptide sequencing” (July 2026) (opens in a new tab)
“I used tirzepatide at 2.5 mg weekly for around six months before moving to fortnightly dosing.”
-
ForumReddit r/MounjaroMaintenance: “Level after 31 days on 2.5mg” (September 2026) (opens in a new tab)
“today I’ll be taking my 2.5mg maintenance dose 31 days after my last dose.”
-
“I have experimented with spacing out my doses and buying the higher dose pens but giving myself smaller doses to stretch out how long a pen lasts.”
-
ForumReddit r/Eloralintide: “1+ year after study update” (June 2026) (opens in a new tab)
“I take the zep when I feel that I need it, not on a schedule and not looking to lose weight anymore weight. Usually shoot every 3-4 weeks.”
Where the numbers come from
Grey-market practice copies the label’s 2.5 mg ladder, spread through community guides such as Stairway to Gray and subreddit wikis. Microdosing grew from telehealth practice and influencer promotion. A September 2026 telehealth preprint describes patients started at 1–2 mg a week, but no trial has tested these doses.
Research notes
“Microdose” is used loosely: telehealth programs call 1–2 mg a microdose, forum users go down to 0.04–0.16 mg, and the idea’s originator says any standard starting dose is not a microdose. Grey-market vial strength and purity are unverified unless tested.
What it is. In plain English.
A dual-hormone drug that produces more weight loss than GLP-1 alone.
A 39-amino-acid peptide built on the GIP hormone backbone and engineered to also hit the GLP-1 receptor, with a fatty-acid chain for once-weekly dosing. Sold here under the code NXP-2P (two receptor targets).
It activates two gut-hormone receptors, GIP and GLP-1. The GLP-1 side curbs appetite and slows digestion; the GIP side appears to improve insulin response and may soften nausea.
Reviewed 2026-10-01.
Structure. What it really looks like.
Experimental
Tirzepatide (teal) bound to the human GLP-1 receptor (gray), one of the two receptors it acts on. Also part of the experiment, but not drawn: a G protein and two antibody fragments.
Missing parts
- The fatty-acid side chain isn’t in this model.
- The last eight of the peptide’s 39 amino acids have no coordinates.
7RGP, Sun et al., 2022. Rendered with Mol* (Sehnal et al., 2021) from RCSB PDB data (Berman et al., 2000).
ExperimentalCryo-EM3.08 Å
Tirzepatide (teal) bound to the human GIP receptor (gray), the other receptor it acts on. Also part of the experiment, but not drawn: a G protein, two antibody fragments and a small molecule bound inside the receptor.
Missing parts
- The fatty-acid side chain isn’t in this model.
- The last seven of the peptide’s 39 amino acids have no coordinates.
PDB 7RBT, Sun et al., 2022. Rendered with Mol* (Sehnal et al., 2021) from RCSB PDB data (Berman et al., 2000).
Specs. The facts at a glance.
- Length
- 39 amino acids + fatty-acid chain
- Sold as
- NXP-2P kit · 10, 15, 20, 30 or 60 mg
- Regulatory status
- FDA-approved in the US as Mounjaro for type 2 diabetes, including pediatric patients 10 and older, and for reducing major cardiovascular events in adults with type 2 diabetes at high cardiovascular risk; and as Zepbound for chronic weight management and moderate-to-severe obstructive sleep apnea in adults with obesity. Approval applies to the labeled products, not research-vial tirzepatide.
- Also known as
- The drug in Mounjaro and Zepbound
Sources. What this page rests on.
Every source behind this page, with what it says and when it was checked, is in the Source library.
Tirzepatide in the Source library
Original overview and research notes · annotated 2026-10-01
Historical collection text. Read alongside the claim corrections above; identity or evidence qualifications may supersede this wording.
Weight loss and blood sugar control
A dual-hormone drug that produces more weight loss than GLP-1 alone.
A 39-amino-acid peptide built on the GIP hormone backbone and engineered to also hit the GLP-1 receptor, with a fatty-acid chain for once-weekly dosing. Sold here under the code NXP-2P (two receptor targets).
It activates two gut-hormone receptors, GIP and GLP-1. The GLP-1 side curbs appetite and slows digestion; the GIP side appears to improve insulin response and may soften nausea.
In SURMOUNT-1, adults with obesity lost about 21% of body weight on the highest dose over 72 weeks. In a head-to-head trial (SURMOUNT-5) it produced more weight loss than semaglutide.
Original status record: FDA-approved as Mounjaro (type 2 diabetes, 2022; reducing heart attack and stroke risk in type 2 diabetes, 2026) and Zepbound (obesity, 2023; obstructive sleep apnea, 2024).
More in Weight & metabolism.
- SemaglutideApproved weight-loss and diabetes drugFDA-approved
- RetatrutideExperimental drug for major weight lossHuman trials
- CagrilintideExperimental appetite drug for weight lossHuman trials
- EloralintideExperimental appetite shot for weight lossHuman trials
- SurvodutideExperimental drug for weight lossHuman trials
- AOD-9604Taken to burn fatHuman trials
- 5-Amino-1MQTaken for fat loss and metabolismAnimal & lab only
- MOTS-cTaken for metabolism and enduranceAnimal & lab only